Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
Launched by DUKE UNIVERSITY · May 12, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating an educational tool about hormone replacement therapy (HRT) for women who have a BRCA1 or BRCA2 mutation and are planning to have a surgery called risk-reducing salpingo-oophorectomy (RRSO). This surgery involves removing the ovaries and fallopian tubes to lower the risk of developing certain cancers. The goal is to help doctors provide better information to their patients before the surgery, so they can make informed choices about their treatment options.
To be eligible for this trial, women must be premenopausal, have a confirmed BRCA1 or BRCA2 mutation, and be scheduled for the RRSO surgery at Duke. Women who have a history of cancer, are postmenopausal, over 50 years old, or unable to understand English cannot participate. If you qualify and choose to join the study, you can expect to learn more about HRT and how it may affect your health after surgery. This trial is currently not recruiting participants yet, but it aims to provide valuable information for women in similar situations.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • BRCA1 or BRCA2 germline mutation
- • scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
- • premenopausal
- Exclusion Criteria:
- • personal history of cancer
- • postmenopausal
- • \>50 years old
- • unable to provide informed consent in English
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Laura Havrilesky
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported